

. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Y Matsumura, M Yasunaga, S Manabe.	Cancer stromal targeting (CAST) therapy and tailored antibody drug conjugate therapy depending on the nature of tumor stroma.	YH Bae, RJ Mrsny, and K Park	In Cancer Targeted Drug Delivery, An Elusive Dream	Springer	New York Heidelberg Dordrecht London	2013	161-181
Kosaka N, Yoshioka Y, Hagiwara K, Tominaga N, Ochiya T	Functional analysis of exosomal microRNA in cell-cell communication research	Takahiro Ochiya	Methods Mol Biol Vol 1024 Circulating MicroRNAs Methods and Protocols	Springer	Germany	2013	1-10

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamada Y, Kiyota N, Fuse N, Kato K, Minami H, Hashizume K, Kuroki Y, Ito Y, Ohtsu A.	A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.	Gastric Cancer	17(1)	161-172	2014
Takahashi H, Kaniwa N, Saito Y, Sai K, Hataguchi T, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Takahashi A, Odakami Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.	J Biosci Bioeng.	116(6)	768-773	2013

Yamada Y, <u>Boku N</u> , <u>Nishina T</u> , <u>Yamaguchi K</u> , <u>Denda T</u> , <u>Tsuji A</u> , <u>Hamamoto Y</u> , <u>Konishi K</u> , <u>Tsuji Y</u> , <u>Amagai K</u> , <u>Ohkawara S</u> , <u>Fujita Y</u> , <u>Nishisaki H</u> , <u>Kawai H</u> , <u>Takahashi A</u> , <u>Mizusawa J</u> , <u>Nakamura K</u> , <u>Ohtsu A</u> .	Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: comparative relative study in Japanese Clinical Oncology Group Trial JCOG9912.	Ann Oncol.	24(10)	2560-2565	2013
<u>Doi T</u> , <u>Muro K</u> , <u>Yoshino T</u> , <u>Furuse N</u> , <u>Ura T</u> , <u>Takahashi D</u> , <u>Feng HP</u> , <u>Shimamoto T</u> , <u>Noguchi K</u> , <u>Ohtsu A</u> .	Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), a novel anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.	Cancer Chemother Pharmacol.	72(3)	643-652	2013
<u>Ohtsu A</u> , <u>Ajani JA</u> , <u>Bai YX</u> , <u>Boung YJ</u> , <u>Chung HC</u> , <u>Pan HM</u> , <u>Sahmoud T</u> , <u>Shen L</u> , <u>Yeh KH</u> , <u>Chin K</u> , <u>Muro K</u> , <u>Kim YH</u> , <u>Ferry D</u> , <u>Tebbutt NC</u> , <u>Al-Batran SE</u> , <u>Smith H</u> , <u>Costantini C</u> , <u>Rizvi S</u> , <u>Lebwohl D</u> , <u>Van Cutsem E</u> .	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.	J Clin Oncol	31(31)	3935-3943	2013
<u>Paoletti X</u> , <u>Oba K</u> , <u>Bang YJ</u> , <u>Bouleberg H</u> , <u>Boku N</u> , <u>Bouché O</u> , <u>Catalano P</u> , <u>Furuse N</u> , <u>Michiels S</u> , <u>Moehler M</u> , <u>Morita S</u> , <u>Ohashi Y</u> , <u>Ohtsu A</u> , <u>Roth A</u> , <u>Rougier P</u> , <u>Sakamoto J</u> , <u>Sargent D</u> , <u>Sasaki M</u> , <u>Shitara K</u> , <u>Thuss-Patience P</u> , <u>Van Cutsem E</u> , <u>Burzykowski T</u> , <u>Buyse M</u>	GASTRIC group. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.	J Natl Cancer Inst.	105(21)	1667-1670	2013

A Takahashi, I, Y Yamamoto, M Yasunaga, Y Koga, J Kuroda, M Takigahira, M Harada, H Saito, T Hayashi, Y Kato, T Kinoshita, N Ohkohchi, I Hyodo, Y <u>Matsumura.</u>	NC-6300, an epirubicin-incorporati ng micelle, exerts higher antitumor activity and the least cardiotoxicity as compared to conventional epirubicin.	Cancer Sci.	104	920-925	2013
Y Hisada, M Yasunaga, S Hanaoka, , Saijou. T Sugino A, Tsuji, T Saga, K Tsumoto, S Manabe., J Kuroda., J Kuratsu, Y <u>Matsumura.</u>	Discovery of an uncovered region in fibrin clots and its clinical significance.	Sci. Rep.	3	2604	2013
Y Koga, S Katayose, N Onoda, T Kasamatsu, T Kato, S Ikeda, M Ishikawa, K Ishitani, Y Hirai, H Matsui, Y <u>Matsumura.</u>	Usefulness of immuno-magnetic beads conjugated with anti-EpCAM antibody for detecting endometrial cancer cells.	J Cancer Therapy	4	1273-1282	2013
M Yasunaga, M Furuta, K Ogata, Y Koga, Y Yamamoto, M Takigahira, Y <u>Matsumura.</u>	The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution.	Sci. Rep.	3	3050	2013
Y Yamamoto, I Hyodo, M Takigahira, Y Koga, M Yasunaga, M Harada, T Hayashi, Y Kato, Y <u>Matsumura</u>	Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model.	Int J Cancer	135	214-223	2014
K Yanagihara, M Takigahira, T Kubo, T Ochiya, T Hamaguchi, Y <u>Matsumura.</u>	Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis from gastric cancer.	Ther. Deliv.	5(2)	129-138	2014

Watanabe A, Yamazaki K, Kinugasa Y, Tsukamoto S, Yamaguchi T, Shiomi A, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, <u>Yasui H</u> .	Influence of primary tumor resection on survival in asymptomatic patients with incurable stage IV colorectal cancer.	Int J Clin Oncol.	Epub ahead of print	Epub ahead of print	2014
Koizumi W, <u>Yamaguchi K</u> , Hosaka H, Takinishi Y, Nakayama N, Hara T, Muro K, Baba H, Sasaki Y, <u>Nishina T</u> , Fuse N, Esaki T, Takagi M, Gotoh M, Sasaki T.	Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.	Br J Cancer	109 (8)	2079-2086	2013
Yamamoto N, Murakami H, <u>Nishina T</u> , Sugio K, <u>Muro K</u> , Takahashi T, Naito T, <u>Yasui H</u> , Akinaga S, Koh Y, <u>Boku N</u>	The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase trial in advanced solid tumors.	Annals of Oncology	24	1653-1659	2013
<u>Yamaguchi K</u> , Sawaki A, <u>Doi T</u> , Satoh T, Yamada Y, Omuro Y, <u>Nishina T</u> , <u>Boku N</u> , Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, <u>Ohtsu A</u>	Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study	Gastric Cancer	16(2)	175-182	2013
Kawano Nagatsuma A, Aizawa M, Kuwata T, <u>Doi T</u> , <u>Ohtsu A</u> , Fujii H, <u>Ochiai A</u>	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma	Gastric Cancer	(Epub ahead of print)	(Epub ahead of print)	2014 Mar 14

Yoshino T, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayana M, Fujino T, <u>Ohtsu A.</u>	HER2-positive gastric cancer	Gastric Cancer	17(1)	1-12	2014
<u>Boku N, Muro K,</u> Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y.	Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer	Invest New Drugs	32(2)	261-70	2014
<u>Kang YK, Muro K,</u> <u>Ryu MH, Yasui H,</u> <u>Nishina T, Ryoo</u> <u>BY, Kamiya Y,</u> <u>Akinaga S, Boku N</u>	A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer	Invest New Drugs.	32(2)	355-61	2014
<u>Hironaka S, Ueda</u> <u>S, Yasui H,</u> <u>Nishina T, Tsuda</u> <u>M, Tsumura T,</u> <u>Sugimoto N,</u> <u>Shimodaira H,</u> <u>Tokunaga S,</u> <u>Moriwaki T, Esaki</u> <u>T, Nagase M,</u> <u>Fujitani K,</u> <u>Yamaguchi K, Ura</u> <u>T, Hamamoto Y,</u> <u>Morita S, Okamoto</u> <u>I, Boku N, Hyodo I</u>	Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial	J Clin Oncol.	31(35)	4438-4444	2013

Paoletti X, Oba K, Bang YJ, Bleiberg H, <u>Boku N</u> , Bouché O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, <u>Ohtsu A</u> , Roth A, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M; on behalf of the GASTRIC group	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis	J Natl Cancer Inst.	105 (21)	1667-70	2013
Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, <u>Boku N</u> , Nishio K, Fukuoka M, Yamamoto N, Nakagawa K.	A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors	Cancer Chemother Pharmacol	72(5)	1063-71	2013
Niwakawa M, Yamaguchi R, Onozawa Y, Yasui H, Taku K, Naito T, Akinaga S, <u>Boku N</u> , Yamamoto N	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors	Cancer Sci	104(8)	1039-44	2013
Fujisaka Y, Onozawa Y, Kurata T, Yasui H, Goto I, Yamazaki K, Machida N, Watanabe J, Shimada H, Shi X, <u>Boku N</u>	First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours	Invest New Drugs	31(1)	108-14	2013
Yoshino T, <u>Yamazaki K</u> , <u>Yamaguchi K</u> , <u>Doi T</u> , <u>Boku N</u> , Machida N, Onozawa Y, Asayama M, Fujino T, <u>Ohtsu A</u>	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer	Invest New Drugs	31(4)	910-7	2013

Bando H, Yoshino T, Shinozaki E, <u>Nishina T</u> , Yamazaki K, <u>Yamaguchi K</u> , Yuki S, Kajiura S, Fujii S, Yamanaka T, <u>Tsuchihara K</u> , <u>Ohtsu A</u> .	Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.	BMC Cancer.	13	405	2013
門脇 重徳、 <u>室圭</u>	MET阻害薬の特徴と臨床開発	腫瘍内科	12(3)	337-345	2013
<u>土原一哉</u>	次世代シーケンス技術を用いたがん薬物療法最適化への試み	癌と化学療法	41	1-6	2014
Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, <u>Ochiya T</u>	Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3 β	Sci Rep	3	2474	2013
Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, <u>Ochiya T</u>	Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis	J Biol Chem	288	10849-10859	2013
Kosaka N, Takeshita F, Yoshioka Y, Hagiwara K, Katsuda T, <u>Ono M</u> , <u>Ochiya T</u>	Exosomal tumor-suppressive microRNAs as novel cancer therapy: "Exocure" is another choice for cancer treatment	Adv Drug Deliv Rev	65	376-382	2013
Suetsugu A, Honma K, Saji S, Moriwaki H, <u>Ochiya T</u> , Hoffman RM	Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models	Adv Drug Deliv Rev	65	383-390	2013
Uchino K, <u>Ochiya T</u> , Takeshita F	RNAi therapeutics and applications of microRNAs in cancer treatment	Jpn J Clin Oncol	43	596-607	2013

Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, <u>Ochiya T</u> , Gotoh N, Kuroda M	Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells	Mol Ther	21	185-191	2013
Asano J, Hirakawa A, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, <u>Fujiwara Y</u>	Use of Cox's Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response	Int J Breast Cancer	2013	Epub	2013
Shimma S, Takashima Y, Hashimoto J, <u>Yonemori K</u> , <u>Tamura K</u> , Hamada A	Alternative two-step matrix application method for imaging mass spectrometry to avoid tissue shrinkage and improve ionization efficiency	J Mass Spectrom	48	1285-1290	2013
<u>Ono M</u> , Tsuda H, Yunokawa M, <u>Yonemori K</u> , Shimizu C, <u>Tamura K</u> , Kinoshita T, <u>Fujiwara Y</u>	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.	Breast Cancer	-	Epub	2013
Yunokawa M, Katsumata N, Yamamoto H, Kodaira M, <u>Yonemori K</u> , Shimizu C, Ando M, <u>Tamura K</u> , <u>Fujiwara Y</u>	A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer	Cancer Chemother Pharmacol	71	1369-1374	2013
Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, <u>Tamura K</u> , Okusaka T	Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma	Br J Cancer	109	739-746	2013

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y	⁶⁴ Cu-DOTA-trastuzuma b PET imaging in patients with HER2-positive breast cancer	J Nucl Med	54	1869-1875	2013
--	---	------------	----	-----------	------